参附注射液联合表柔比星和紫杉醇治疗三阴性乳腺癌的临床价值

Clinical Evaluation of Shenfu Injection Combined with Epirubicin and Paclitaxel in the Treatment of Triple Negative Breast Cancer

目的:探究参附注射液联合表柔比星和紫杉醇治疗三阴性乳腺癌的效果。方法:将2014年6月至2016年12月肇庆市高要人民医院收治的60例三阴性乳腺癌患者随机数字表法分为两组,各30例,对照组给予表柔比星和紫杉醇治疗,观察组在对照组基础上加用参附注射液治疗,对两组治疗效果进行综合评价。结果:观察组患者治疗后肿瘤直径、癌胚抗原(CEA)、癌抗原125(CA125)水平均有所降低,且与对照组比较,差异具有统计学意义(P<0.05);观察组患者白细胞及中性粒细胞减少发生率分别为60.0%、40.0%,显著低于对照组差异具有统计学意义(P<0.05);观察组治疗后总有效率为83.3%,显著高于对照组的63.3%,差异具有统计学意义(P<0.05)。结论:参附注射液联合表柔比星和紫杉醇治疗三阴性乳腺癌,效果显著。

Objective To explore the effect of Shenfu injection combined with epirubicin and paclitaxel in the treatment of triple negative breast cancer. Methods 60 cases of three negative breast cancer patients in Zhaoqing Gaoyao people＇s hospital in June 2014 to December 2016 were divided into 30 cases, each group was treated with epirubicin and paclitaxel. The observation group was treated with Shenfu injection on the basis of the control group, and the therapeutic effects of the two groups were evaluated comprehensively. Results In the observation group, the tumor diameter, carcinoembryonic antigen（CEA）, and cancer antigen 125（CA125） levels decreased after treatment, and there was a statistically significant difference（P〈0.05） between the observation group and the control group; The incidence of granulocytopenia was 60.0 % and 40.0 %, respectively, which was significantly lower than that of the control group（P〈0.05）. The total effective rate was 83.3 % in the observation group, which was significantly higher than that in the control group（63.3 %）. The difference was statistically significant（P〈0.05）. Conclusion Shenfu injection combined with epirubicin and paclitaxel treatment of triple negative breast cancer, the effect is significant.